What Is HTD1801 and Why Does It Matter for Type 2 Diabetes? A recent Phase III clinical trial on the investigational drug HTD1801, combined with metformin, shows promise for improving Type 2 diabetes management. Despite patients taking metformin, many struggled with blood glucose control, prompting the investigation into HTD1801, derived from berberine and ursodeoxycholic acid. Results revealed an average HbA1c reduction of 1.2 percentage points compared to 0.7 points with a placebo, indicating HTD1801's effectiveness. The medication also exhibited a favorable safety profile, primarily causing mild diarrhea. This represents a shift in understanding metabolic disease, highlighting the need for multi-system therapeutic approaches rather than solely focusing on glucose levels....
Loading...
